Previous Publications
2023
March 2023
- Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Nature Communications, March 7, 2023 - Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain
Cell Reports, March 6, 2023 - Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
Lancet Regional Health, March 6 2023
- Sniffer dogs performance is stable over time in detecting COVID-19 positive samples and agrees with the rapid antigen test in the field
Nature Scientific Reports, March 5, 2023
- Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later
Science Translational Medicine, March 1, 2023
February 2023
- Excess cardiovascular mortality across multiple COVID-19 waves in the United States from March 2020 to March 2022
Nature Cardiovascular Research, February 27, 2023 - SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses
Immunity, February 27, 2023 - Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: a retrospective cohort study using real-world data
Lancet regional health, February 27, 2023 - Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial
JAMA, February 20, 2023 - Transcriptionally active nasopharyngeal commensals and opportunistic microbial dynamics define mild symptoms in the COVID 19 vaccination breakthroughs
PLoS Pathogens, February 17, 2023 - Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
Immunity, February 15, 2023 - An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination
Science Translational Medicine, February 15, 2023 - Why we need a deeper understanding of the pathophysiology of long COVID
Lancet Infectious Diseases, February 14, 2023 - Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination
J Virol, February 13, 2023 - A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike
Cell, February 10, 2023 - Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis
Lancet, February 8, 2023 - Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
Lancet Regional Health, February 5, 2023 - ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5
Lancet Infectious Diseases, February 3, 2023 - High-depth sequencing characterization of viral dynamics across tissues in fatal COVID-19 reveals compartmentalized infection
Nature Communications, February 2, 2023 - VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
NEJM, February 2, 2023
January 2023
- Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
Lancet infectious diseases, January 30, 2023 - The type I interferon antiviral response in the choroid plexus and the cognitive risk in COVID-19
Nature immunology, January 30, 2023 - Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
Cell Reports, January 26, 2023 - Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
Cell Reports, January 26, 2023 - Effectiveness of Bivalent Boosters against Severe Omicron Infection
NEJM, January 25, 2023 - Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
NEJM, January 25, 2023 - Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study
eBioMedicine, January 24, 2023 - Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection
Cell Research, January 25, 2023 - Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals
ISME Journal, January 23, 2023 - Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
Trends in Molecular Medicine, January 22, 2023 - The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials
Lancet Infectious Diseases, January 19, 2023 - Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
NEJM, January 18, 2023 - Protection against Reinfection with the Omicron BA.2.75 Subvariant
NEJM, January 18, 2023 - Molecular fate-mapping of serum antibody responses to repeat immunization
Nature, January 16, 2023 - Long COVID: major findings, mechanisms and recommendations
Nature Reviews Microbiology, January 13, 2023 - Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Nature Communications, January 12, 2023 - Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium
Cell Reports, January 11, 2023 - Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
NEJM, January 11, 2023 - Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation
Nature, January 11, 2023 - Innate immune evasion strategies of SARS-CoV-2
Nature Reviews Microbiology, January 11, 2023 - SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19
Nature Communications, January 10, 2023 - SARS-CoV-2 Omicron subvariants Spike recognition and neutralization elicited after the third dose of mRNA vaccine
Cell Reports, January 9, 2023 - Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
NEJM, January 5, 2023 - MPXV Transmission at a Tattoo Parlor
NEJM, January 5, 2023 - B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response
Nature Communications, January 4, 2023 - Features and risk factors of post-COVID-19 syndrome: Findings from a longitudinal study in Bangladesh
Lancet Regional Health, January 2, 2023 - Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans
Nature Microbiology, January 2, 2023 - Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave
Nature Medicine, January 2, 2023 - Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
Lancet Infectious Diseases, January 2023 - Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
NEJM December 21, 2022 - Rapid emergence of omicron sublineages expressing spike protein R346T
Lancet Regional Health, January 2023
2022
DECEMBER 2022
- Drug Sensitivity of Currently Circulating Mpox Viruses
NEJM, December 28, 2022 - Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Nature Communications, December 27, 2022 - Clonal replacement sustains long-lived germinal centers primed by respiratory viruses
Cell, December 23, 2022 - Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
Science Immunology, December 23, 2022 - Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study
Lancet infectious disease, December 22, 2022 - Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
NEJM December 21, 2022 - Persistent post–COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium
Science translational medicine, December 21, 2022 - Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children
Science, December 20, 2022 - Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
Nature reviews immunology, December 20, 2022 - Prevalence of post-COVID Condition 12 Weeks after Omicron Infection Compared to Negative Controls and Association with Vaccination Status
Clinical Infectious Diseases, December 15, 2022 - Immune recall improves antibody durability and breadth to SARS-CoV-2 variants
Science Immunology, December 16, 2022 - A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines
NEJM, December 15, 2022 - Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Cell, December 13, 2022
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Cell, December 13, 2022 - Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention
Matter, December 12, 2022 - Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies
Cell Immunity, December 11, 2022 - Recombination shapes the 2022 monkeypox (mpox) outbreak
Cell Med, December 9, 2022 - Breakthrough Infections after Postexposure Vaccination against Mpox
NEJM, December 7, 2022 - Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
NEJM, December 7, 2022
- An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2
Cell host and microbe, December 8, 2022 - Monkeypox: potential vaccine development strategies
Trends in Pharmacological Sciences, December 8, 2022 - Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
The Lancet Microbe, December 6, 2022 - FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Nature, December 5, 2022 - Defining antigen targets to dissect vaccinia virus and mpox virus-specific T cell responses in humans
Cell Host & Microbe, December 3, 2022 - Gradual emergence followed by exponential spread of the SARS-CoV-2 Omicron variant in Africa
Science, December 2, 2022 - Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
NEJM, December 1, 2022
NOVEMBER 2022
- Tecovirimat for Monkeypox in Central African Republic under Expanded Access
NEJM, November 30, 2022 - High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection
Nature communications, November 28, 2022 - Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Science, November 27, 2022 - Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity
Nature communications, November 25, 2022 - A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins
Nature chemical biology, November 21, 2022 - Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
The Lancet Infectious Diseases, November 18, 2022 - Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
Science Immunology, November 18, 2022 - Monkeypox
Lancet, November 17, 2022 - Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
Science Immunology, November 15, 2022 - Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial
Nature Microbiology, November 14, 2022 - Host genetic variability and determinants of severe COVID-19
Trends in Genetics, November 12, 2022 - Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in macaques
Cell, November 10, 2022 - Acute and postacute sequelae associated with SARS-CoV-2 reinfection
Nature Medicine, November 10, 2022 - Acute and postacute sequelae associated with SARS-CoV-2 reinfection
Nature Medicine, November 10, 2022 - Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Nature, November 9, 2022 - Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection
Nature Communications, November 7, 2022 - Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations
Nature Microbiology, November 7, 2022 - Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
J Exp Med, November 7, 2022 - Shared genetic influences between blood analyte levels and risk of severe COVID-19
Cell Reports, November 6, 2022 - Monkeypox: epidemiology, pathogenesis, treatment and prevention
Nature, Signal Transduction and Targeted Therapy, November 2, 2022 - Durable spike-specific T-cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination
Science Immunology, November 1, 2022 - Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia
Nature Communications, November 1, 2022
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2
EbioMedicine, November 1, 2022
OCTOBER 2022
- Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
Nature Communications, October 29, 2022 - Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Science, October 27, 2022 - Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
Cell Reports, October 26, 2022 - Pre-infection antiviral innate immunity contributes to sex differences in SARS-CoV-2 infection
Cell systems, October 26, 2022 - Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
Cell Reports, October 26, 2022 - Pre-infection antiviral innate immunity contributes to sex differences in SARS-CoV-2 infection
Cell systems, October 26, 2022 - Monkeypox
NEJM, October 26, 2022 - Sterilizing immunity: Understanding COVID-19
Immunity, October 23 2022 - Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
Nature Communications, October 23, 2022 - Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Science, October 20, 2022 - Multiple lineages of monkeypox virus detected in the United States, 2021–2022
Science, October 20, 2022 - Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
Nature Medicine, October 2022 - Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
NEJM, October 19, 2022 - Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
Lancet, October 15, 2022 - Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark
Lancet, October 18, 2022 - Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
Nature Medicine, Oct 18, 2022 - Retrospective detection of monkeypox virus in the testes of nonhuman primate survivors
Nature Microbiology, Oct 17, 2022 - Therapeutic advances in COVID-19
Nature Reviews Nephrology, October 17, 2022 - SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa
Nature Communications, October 17, 2022 - Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
NEJM, October 12, 2022 - Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
NEJM, October 12, 2022 - Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses
PNAS, October 10, 2022 - Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
eBioMedicine, October 10, 2022 - Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
Cell Host & Microbe, October 9, 2022 - Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals
Nature Scientific Reports, October 7, 2022 - The Neurobiology of Long COVID
Neuron, Oct 6, 2022 - A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
Cell Reports, October 5, 2022 - Long-term neurological sequelae of SARS-CoV-2 infection
Nature Medicine, October 3, 2022 - Monkeypox trial to begin in DR Congo
Lancet Infectious Diseases, October 1, 2022
SEPTEMBER 2022
- Lingering cardiac involvement in previously well people after mild COVID-19
Nature Medicine, September 26 2022 - A distinct symptom pattern emerges for COVID-19 long-haul: a nationwide study
Nature, September 23, 2022 - Monkeypox: A public health emergency in Brazil
Lancet Regional Health, Sep 23, 2022 - SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages
Science translational medicine, Sep 22, 2022 - Monkeypox: Where are the racial disparities?
Lancet regional Health, Sep 22, 2022 - Monkeypox transmission—what we know so far
Lancet Respiratory medicine, Sep 22, 2022 - SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression
Science, September 21, 2022 - SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression
Science, September 21, 2022 - Differential proinflammatory activities of Spike proteins of SARS-CoV-2 variants of concern
Science Direct, September 16, 2022 - A Bivalent Omicron-Containing Booster Vaccine against Covid-19
NEJM, September 16, 2022 - Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection
NEJM, September 14, 2022 - Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
Science Translational Medicine, September 14, 2022 - Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants including BA.4 and BA.5
Cell, September 13, 2022 - Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19
Science, September 9, 2022 - Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors
Nature Chemical biology, September 8, 2022 - Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
NEJM, September 7, 2022 - Dissecting the role of the human microbiome in COVID-19 via metagenome-assembled genomes
Nature Communications, September 6, 2022
- Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial
The Lancet Respiratory Medicine, September 5, 2022 - Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study
The Lancet Global Health, September 1, 2022
AUGUST 2022
- SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis
PNAS, August 30, 2022 - A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
Nature Communications, August 30, 2022 - Spike Protein-independent Attenuation of SARS-CoV-2 Omicron Variant in Laboratory Mice
Cell Reports, August 28, 2022 - Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2
Cell Reports Medicine, August 28, 2022 - Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
NEJM, August 18, 2022 - Asymptomatic Infection? Another Reason to Consider Monkeypox a Disease of Public Health Concern
Annals of Internal Medicine, August 16, 2022 - Multiple BCG vaccinations for prevention of COVID-19 and other infectious diseases in Type 1 diabetes
Cell Reports Medicine, August 15, 2022 - Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection
Cell Reports Medicine, August 15, 2022 - Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period
Nature Communications, August 13, 2022 - An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion
Science Immunology, August 11, 2022 - The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination
Immunity, August 11, 2022 - Update on the Monkeypox Outbreak
JAMA Network, August 11, 2022 - Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
NEJM, August 11, 2022 - Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2
Molecular Therapy, August 9, 2022 - CD8 T Cells Contribute to Vaccine Protection Against SARS-CoV-2 in Macaques
Science Immunology, Aug 9, 2022 - Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study
The Lancet, August 6, 2022 - Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
Cell Reports Medicine, August 4, 2022 - Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron
Cell, Host & Microbe August 4, 2022 - A first update on mapping the human genetic architecture of COVID-19
Nature, August 3, 2022 - Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future Considerations
NEJM, August 3, 2022 - Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel
JAMA Network, August 2, 2022
JULY 2022
- Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera
eBioMedicine July 29, 2022 - Profiling post-COVID syndrome across different variants of SARS-CoV-2
MedRxiv, July 31, 2022 - Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19
Nature. July 28, 2022 - An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
Science Immunology, July 29, 2022 - The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic
Science, July 26, 2022 - The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2
Science, July 26, 2022 - Symptoms and risk factors for long COVID in non-hospitalized adults
Nature Medicine, July 25, 2022 - SARS-CoV-2 epitope–specific CD4+ memory T cell responses across COVID-19 disease severity and antibody durability
Science Immunology, July 22, 2022 - Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
Science, July 19, 2022 - Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
The Lancet Infectious Diseases, July 15, 2022 - Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants
NEJM, July 14, 2022 - Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants
iScience, July 14, 2022 - Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection
JAMA Network Open July 13, 2022 - Protection of SARS-CoV-2 natural infection against reinfection with the BA.4 or BA.5 Omicron subvariants
MedRxiv, July 12, 2022 - Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
MedRxiv, July 12, 2022 - Monoclonals for patients hospitalised with COVID-19
The Lancet Respiratory Medicine, July 8, 2022 - Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera
Nature Communication, July 7, 2022 - SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice
Science Translational Medicine, July 7, 2022 - Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
NEJM, July 6, 2022 - SARS-CoV-2 3CLpro mutations confer resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-function system
Biorxiv, July 4, 2022 - Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccine
Medrxiv, July 4, 2022 - Global monkeypox outbreak
Lancet Infectious Diseases July 1, 2022
JUNE 2022
- Why does viral RNA sometimes persist after recovery from acute infections? – PMC (nih.gov)
PLoS Biology, June 2022
GVN Center Director Diane Griffin (Johns Hopkins Bloomberg School of Public Health - IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2
Science Immunology, June 30, 2022 - A broad and potent neutralization epitope in SARS-related coronaviruses
PNAS June 29, 2022 - Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution
Science, June 28, 2022 - Persistent 129Xe MRI Pulmonary and CT Vascular Abnormalities in Symptomatic Individuals with Post-Acute COVID-19 Syndrome
Radiology, June 28, 2022 - A Bivalent Omicron-containing Booster Vaccine Against Covid-19
MedRxiv, June 25, 2022 - Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up
eClinicalMedicine, June 25, 2022 - Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
NEJM, June 22, 2022 - SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters
Nature Communications, June 20, 2022 - Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant
Cell Reports Medicine, June 19, 2022 - What SARS-CoV-2 does to our brains
Immunity, June 19, 2022 - BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Nature, June 17, 2022 - Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
NEJM, June 17, 2022 - Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2
The Lancet, June 17, 2022 - Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
JEM, June 15, 2022 - Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
Science, June 14, 2022 - Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases
The Lancet, June 11, 2022 - Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
The Lancet, June 11, 2022 - Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
NEJM, June 9, 2022 - Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
The Lancet Respiratory Medicine, June 9, 2022 - SARS-CoV-2 infection relaxes peripheral B cell tolerance
J Exp Med (2022) 219 (6): e20212553. - Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
Science Immunology, June 2, 2022
MAY 2022
- Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
BMJ, May 2022 - Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA.2 wave: an observational study
medRxiv, May 30, 2022 - Efficacy study of Paxlovid and Molnupiravir in real-world settings shows positive results
News Medical, May 24, 2022 - Genomic characterization of the recent monkeypox outbreak
bioRxiv, June 3, 2022 - Mask wearing in community settings reduces SARS-CoV-2 transmission
PNAS, May 31, 2022 - Long COVID after breakthrough SARS-CoV-2 infection
Nature Medicine, May 25, 2022 - Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum
bioRxiv, May 23, 2022 - Impact of natural selection on global patterns of genetic variation and association with clinical phenotypes at genes involved in SARS-CoV-2 infection
PNAS, May 17, 2022 - Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
NEJM, May 18, 2022 - Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
The Lancet eClinicalMedicine, May 12, 2022 - Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study
The Lancet Respiratory Medicine, May 11, 2022 - Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
NEJM, May 11, 2022 - SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
Cell Host & Microbe, May 5, 2022 - Omicron infection enhances Delta antibody immunity in vaccinated persons
Nature, May 6, 2022 - Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
The Lancet, May 2, 2022 - Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
Cell, May 4, 2022
APRIL 2022
- Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection
JAMA, April 29, 2022 - An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
Science Immunology, April 26, 2022 - LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Cell Reports, April 24, 2022 - Regional replacement of SARS-CoV-2 variant BA.1 with BA.2 as observed through wastewater surveillance
medRxiv, April 22, 2022 - Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
NEJM, April 20, 2022 - Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2—A Report From the US National COVID Cohort Collaborative
JAMA, April 15, 2022 - Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
Emerging Infectious Diseases, April 2022 - Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
NEJM, April 13, 2022 - Persistent COVID-19 symptoms in a community study of 606,434 people in England
Nature Communications, April 12, 2022 - Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2
Nature Medicine, April 8, 2022 - Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
NEJM, April 5, 2022 - Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US
JAMA Pediatrics, April 1, 2022
MARCH 2022
- Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
The Lancet Infectious Diseases, March 31, 2022 - Effect of Early Treatment with Ivermectin among Patients with Covid-19
NEJM, March 30, 2022 - Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
The Lancet Microbe, March 28, 2022 - SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses
The Lancet, March 25, 2022 - Risks and burdens of incident diabetes in long COVID: a cohort study
The Lancet Diabetes and Endocrinology, March 21, 2022 - Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant–Infected Vaccinees
Emerging Infectious Diseases, March 15, 2022 - Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
NEJM, March 16, 2022 - A broad and potent neutralization epitope in SARS-related coronaviruses
BioRxiv, March 14, 2022 - Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Infectious Diseases, March 11, 2022 - Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
NEJM, March 9, 2022 - SARS-CoV-2 is associated with changes in brain structure in UK Biobank
Nature, March 7, 2022 - Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters
bioRxiv, March 4, 2022 - Antibody evasion properties of SARS-CoV-2 Omicron sublineages
Nature, March 3, 2022
FEBRUARY 2022
- Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant
MedRxiv, February 28, 2022 - Large-scale implementation of rapid antigen testing system for COVID-19 in workplaces
Science Advances, February 25, 2022 - Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose
BioRxiv, February 15, 2022 - Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study
The Lancet Child & Adolescent Health, February 18, 2022 - The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
Nature Communications, February 15, 2022 - Co-infection with SARS-COV-2 Omicron and Delta Variants Revealed by Genomic Surveillance
MedRxiv, February 15, 2022 - Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
CDC, February 11, 2022 - Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
Nature, February 9, 2022 - Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study
MedRxiv, February 7, 2022 - Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
Science Immunology, February 3, 2022 - Durability of Omicron-neutralizing serum activity following mRNA booster immunization in elderly individuals
MedRxiv, February 2, 2022
JANUARY 2022
- Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households
MedRxiv, January 30, 2022 - Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021
MedRxiv, January 27, 2022 - Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVD-19 respiratory disease
Cell Immunity, January 25, 2022 - Nasally-delivered interferon-{lambda} protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including Omicron
BioRxiv, January 24, 2022 - Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2)
MedRxiv, January 23, 2022 - Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination
MedRxiv, January 17, 2022 - Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant
MedRxiv, January 16, 2022 - Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron
MedRxiv, January 11, 2022 - Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children
MedRxiv, January 10, 2022 - Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
MedRxiv, January 8, 2022 - The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
MedRxiv, January 3, 2022
2021
DECEMBER 2021
- Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection
Science Translational Medicine, December 30, 2021 - COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer
Cancer Cell, December 29, 2021 - Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
The Lancet, December 20, 2021 - Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
NEJM, December 16, 2021 - Simulation of the omicron variant of SARS-CoV-2 shows broad antibody escape, weakened ACE2 binding, and modest increase in furin binding
BioRxiv, December 15, 2021 - Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
MedRxiv, December 14, 2021 - SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021
CDC, December 10, 2021 - Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
The Lancet, December 6, 2021 - Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa
Medrxiv, December 2, 2021
NOVEMBER 2021
- Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant
JAMA, November 24, 2021 - Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
NEJM, November 24, 2021 - Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Science, November 23, 2021 - Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
Nature Communications, November 18, 2021 - Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet, November 17, 2021 - Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
The Lancet Microbe, November 15, 2021 - Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
The Lancet, November 11, 2021 - Evaluation of the BNT162b2 Vaccine against Covid-19 in 5-to-11-Year-Olds
NEJM, November 9, 2021 - Evaluation of the BNT162b2 Vaccine against Covid-19 in 5-to-11-Year-Olds
NEJM, November 9, 2021 - A novel SARS-CoV-2 related coronavirus in bats from Cambodia
Nature Communications, November 9, 2021 - Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles
Science, November 4, 2021 - Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
NEJM, November 3, 2021
OCTOBER 2021
- Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
The Lancet Global Health, October 27, 2021 - Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
NEJM, October 27, 2021 - Genomic epidemiology and the role of international and regional travel in the SARS-CoV-2 epidemic in Zimbabwe: a retrospective study of routinely collected surveillance data
The Lancet Global Health, October 22, 2021 - Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
The Lancet, October 21, 2021 - Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination
Nature, October 21, 2021 - COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women
Science Translational Medicine, October 19, 2021 - Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
The Lancet Respiratory Medicine, October 18, 2021 - Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
NEJM, October 15, 2021 - Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021
CDC, 2021 - Immunogenicity of a BNT162b2 vaccine booster in health-care workers
The Lancet Microbe, October 11, 2021 - Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
NEJM, October 6, 2021 - Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
The Lancet, October 4, 2021 - The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant
Cell Molecular Therapy, October 1, 2021 - The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
The Lancet Microbe, October 1, 2021
SEPTEMBER 2021
- COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
The Lancet Respiratory Medicine, September 29, 2021 - High affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines
Cell Reports, September 24, 2021 - Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
NEJM, September 23, 2021 - Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
The Lancet Infectious Diseases, September 22, 2021 - Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against re-infection with B.1.1.7 and B.1.351 variants
Science Translational Medicine, September 21, 2021 - High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
Nature, September 20, 2021 - Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
Science, September 14, 2021 - SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
NJEM, September 16, 2021 - Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
The Lancet Infectious Disease, September 9, 2021 - A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa
Science, September 9, 2021 - Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Science Immunology, September 2, 2021 - Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
The Lancet, September 1, 2021
AUGUST 2021
- New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
CDC, August 27, 2021 - Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
The Lancet, August 27, 2021 - Profiling CD8+ T Cell Epitopes of COVID-19 Convalescents Reveals Reduced Cellular Immune Responses to SARS-CoV-2 Variants
Cell Reports, August 26, 2021 - Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
NEJM, August 25, 2021 - mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern
BioRxiv, August 23, 2021 - A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
Cell, August 18, 2021 - The Origins of SARS-CoV-2: A Critical Review
Cell, August 18, 2021 - SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
The Lancet Correspondence, August 17, 2021 - Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
The Lancet Infectious Diseases, August 16, 2021 - Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Science, August 12, 2021 - Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
NEJM, August 11, 2021 - Performance of saliva and mid-turbinate swabs for detection of the beta variant in South Africa
The Lancet Infectious Disease, August 4, 2021 - Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals
Cell Reports, August 3, 2021 - Broad betacoronavirus neutralization by a stem helix–specific human antibody
Science, August 3, 2021 - Longitudinal analysis of SARS-CoV-2 seroprevalence using multiple serology platforms
Cell iScience, August 1, 2021
JULY 2021
- Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021
CDC, July 30, 2021 - Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
NEJM, July 28, 2021 - Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Nature Communications, July 26, 2021 - Systemic IL-15, IFN-γ and IP-10/CXCL10 Signature Associated with Effective Immune Response to SARS-CoV-2 in BNT162b2 mRNA Vaccine Recipients
Cell Reports, July 22, 2021 - Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
NEJM, July 21, 2021 - Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France
The Lancet, July 13, 2021 - Minute-scale detection of SARS-CoV-2 using a low-cost biosensor composed of pencil graphite electrodes
PNAS, July 27, 2021 - Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Nature Medicine, July 14, 2021 - Systems vaccinology of the BNT162b2 mRNA vaccine in humans
Nature, July 12, 2021 - Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Nature, July 8, 2021 - A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation
Cell, July 6, 2021
JUNE 2021
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
NEJM, June 30, 2021 - Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Nature, June 30, 2021 - SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Nature, June 28, 2021 - Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
Science, June 24, 2021 - Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
Nature, June 23, 2021 - In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Nature, June 21, 2021 - Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer
Cancer Cell, June 18, 2021 - SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
Cell, June 14, 2021 - Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Nature, June 14, 2021 - Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
CDC, June 8, 2021 - SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2
Cell, June 8, 2021 - Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
NEJM, June 2, 2021
MAY 2021
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
NEJM, May 27, 2021 - SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
Science Immunology, May 25, 2021 - Activate-2: a Double-blind Randomized Trial of BCG Vaccination Against Covid-19 in Individuals at Risk
Medrxiv, May 24, 2021 - Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Science, May 20, 2021 - Analysis of 472,688 severe cases of COVID-19 in Brazil showed lower mortality in those vaccinated against influenza
Medrxiv, May 14, 2012 - Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues.
Proc Natl Acad Sci, May 25, 2021 - Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
Nature, May 16, 2021 - Do coronavirus genes slip into human chromosomes?
Science, May 14, 2021 - Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women
JAMA, May 13, 2021 - Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues
PNAS, May 2021 - Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts
Nature, May 6, 2021 - Association between ACE2 and TMPRSS2 nasopharyngeal expression and COVID-19 respiratory distress
Nature, May 6, 2021 - Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
NEJM, May 5, 2021 - Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
NEJM, May 5, 2021 - Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
The Lancet, May 5, 2021 - Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset
Cell, May 4, 2021
APRIL 2021
- Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Science, April 30, 2021 - Conformational flexibility and structural variability of SARS-CoV2 S protein
Cell, April 30, 2021 - Longitudinal proteomic analysis of plasma from patients with severe COVID-19 reveal patient survival-associated signatures, tissue-specific cell death, and cell-cell interactions
Cell, April 30, 2021 - Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients
Cell, April 30, 2021 - SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study
The Lancet, April 29, 2021 - Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Cell Medicine, April 20, 2021 - Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Cell, April 20, 2021 - Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization
Cell Host and Microbe, April 17, 2021 - BNT162b2 Vaccination Effectively Prevents the Rapid Rise of SARS-CoV-2 Variant B.1.1.7 in high risk populations in Israel
Cell, April 17, 2021 - Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
Nature, April 16, 2021 - Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
NEJM, April 16, 2021 - Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Science, April 14, 2021 - Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues
Science, April 12, 2021 - Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis
The Lancet, April 12, 2021
MARCH 2021
- TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation
Cell, March 30, 2021 - Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States
Cell, March 30, 2021 - Increased transmissibility of the B.1.1.7 SARS-CoV-2 variant: Evidence from contact tracing data in Oslo, January to February 2021
Medrxiv, March 30, 2021 - Enrichment of SARS-CoV-2 entry factors and interacting intracellular genes in peripheral immune cells
Biorxiv, March 29, 2021 - A Novel Diagnostic Test to Screen SARS-CoV-2 Variants Containing E484K and N501Y Mutations
Medrxiv, March 29, 2021 - Recombinant SARS-CoV-2 genomes involving lineage B.1.1.7 in the UK
Virological.org, March 17, 2021 - Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases
Nature, March 15, 2021 - FDA Fact sheet for health care providers: emergency use authorization (EUA) of bamlanivimab.
FDA, March 2021 - Low SARS-CoV-2 Transmission in Elementary Schools — Salt Lake County, Utah, December 3, 2020–January 31, 2021
CDC, March 26, 2021 - Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
Nature, March 25, 2021 - SARS-CoV-2 infection of the oral cavity and saliva
Nature, March 25, 2021 - New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
NEJM, March 24, 2021 - The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study
Lancet, March 24, 2021 - Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
NEJM, March 23, 2021 - Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
NEJM, March 23, 2021 - Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study
The Lancet, March 20-26, 2021 - SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Cell, March 20, 2021 - Does prior immunization with measles, mumps, and rubella vaccines contribute to the antibody response to COVID-19 antigens?Iran J Immunol, March 18, 2021
- Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
BMJ, March 10, 2021
FEBRUARY 2021
- Impact of the influenza vaccine on COVID-19 infection rates and severity
American Journal of Infection Control, February 22, 2021 - MMR Vaccination: A Potential Strategy to Reduce Severity and Mortality of COVID-19 Illness
American Journal of Medicine, February 1, 2021 - The emergence and ongoing convergent evolution of the N501Y lineages coincided with a major global shift in the SARS-Cov-2 selective landscape
Virological, February 13, 2021 - Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil
CDC, February 2021 - What to know about J&J’s FDA-authorized one-shot COVID-19 vaccine
Science News, February 27, 2021 - Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
NEJM, February 25, 2021 - Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
NEJM, February 25, 2021 - Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
Authorea, February 24, 2021 - Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody | Science
Science, February 19, 2021 - Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine (Moderna)— Preliminary Report
- NEJM, February 17, 2021
- Neutralizing Activity of BNT162b2 (Pfizer)-Elicited Serum — Preliminary Report
NEJM, February 17, 2021 - Humoral signatures of protective and pathological SARS-CoV-2 infection in children
Nature Medicine, February 12, 2021
JANUARY 2021
2020
- Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
mBio, November 2, 2020 - The effect of influenza vaccination on trained immunity: impact on COVID-19
Medrxiv, October 16, 2020 - Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil
BMJ, 2020